BioNexus Gene Lab Corp. Cash Equivalents, at Carrying Value
BioNexus Gene Lab Corp. (BGLC) had Cash Equivalents, at Carrying Value of $1.09 million as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2025-05-15
- 2025-03-31: Cash Equivalents, at Carrying Value $1.09M.
- 2024-12-31: Cash Equivalents, at Carrying Value $1.58M.
- 2024-09-30: Cash Equivalents, at Carrying Value $2.06M.
- 2024-06-30: Cash Equivalents, at Carrying Value $2.20M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2025-03-31 | $1.09M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.58M 10-Q · filed 2025-05-15 |
| 2024-09-30 | $2.06M 10-Q · filed 2024-11-15 |
| 2024-06-30 | $2.20M 10-Q · filed 2024-08-14 |
| 2023-12-31 | $2.62M 10-K · filed 2025-04-15 |
| 2021-12-31 | $2.12M 10-K · filed 2022-04-06 |
| 2020-12-31 | $2.79M 10-K · filed 2022-04-06 |
| 2019-03-31 | $1.21M 10-Q · filed 2019-05-15 |
| 2018-03-31 | $1.22M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |